Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Shenghe (China) Biopharmaceutical Co. Ltd. maintains 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed among 3 distinct examiners, ensuring that no single official is overwhelmed by the company's current filings. Furthermore, the portfolio spans 3 distinct art units, indicating that the pending applications cover diverse biological or pharmaceutical sub-sectors. This variety requires the legal team to maintain expertise across multiple specialized examination groups.
CUNNINGCHEN, KATHLEEN MARY is identified as the busiest examiner with 1 pending office action. This figure matches the workload of the other examiners, as the 3 total actions are spread across 3 individuals. Because the busiest examiner pending count is 1, the prosecution risk is diversified across multiple USPTO personnel. This arrangement requires legal teams to adapt to the specific preferences and styles of three different examiners simultaneously. The lack of concentration among examiners suggests that the company's success is not tied to a single official, but rather to a broad range of examiner interactions across the 3 art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CUNNINGCHEN, KATHLEEN MARY | 1 | 62.5% | +60.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | — |
| Art Unit | Apps |
|---|---|
| 1646 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18694554 | HETERODIMERIC PROTEIN AND APPLICATION THEREOF | CUNNINGCHEN, KATHLEEN MARY | 1646 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 22, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialShenghe (China) Biopharmaceutical Co. Ltd. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Kathleen Mary Cunningchen has the most, with 1 of Shenghe (China) Biopharmaceutical Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
